A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF ALTO-300 WITH AN OPEN-LABEL EXTENSION IN ADULTS WITH MAJOR DEPRESSIVE DISORDER

Status: Recruiting

Eligibility Criteria

Sex: Male or Female
Age Group: 18 years and over
This study is NOT accepting healthy volunteers

Inclusion Criteria:

- ages 18-70 years old - diagnosed with moderate to severe major depressive disorder (MDD) - currently taking one approved antidepressant medication (SSRI, SNRI, or bupropion) for at least 6 weeks with no recent dose changes

Exclusion Criteria:

- diagnosed with fibromyalgia - pregnant or breastfeeding

Conditions & Interventions

Conditions:
Mental Health & Addiction
Keywords:
agomelatine, ALTO-300, depression, Major Depressive Disorder, MDD

More Information

Description: The purpose of this study is to evaluate the safety and effectiveness of ALTO-300, an investigational medication being studied for adults with Major Depressive Disorder (MDD). This study will compare ALTO-300 to a placebo to learn more about how the medication may improve symptoms of depression and to identify factors that may help predict who is most likely to benefit from treatment.
Study Contact: Dariush Kaveh - kave0005@umn.edu
Principal Investigator: Cristina Albott
Phase: PHASE2
IRB Number: STUDY00027511